Intech Investment Management LLC Purchases Shares of 12,647 HilleVax, Inc. (NASDAQ:HLVX)

Intech Investment Management LLC acquired a new stake in shares of HilleVax, Inc. (NASDAQ:HLVX) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 12,647 shares of the company’s stock, valued at approximately $26,000.

A number of other institutional investors have also recently made changes to their positions in HLVX. SG Americas Securities LLC increased its holdings in shares of HilleVax by 61.6% in the fourth quarter. SG Americas Securities LLC now owns 18,145 shares of the company’s stock worth $38,000 after purchasing an additional 6,916 shares during the last quarter. Ieq Capital LLC increased its stake in HilleVax by 71.1% in the 4th quarter. Ieq Capital LLC now owns 22,495 shares of the company’s stock worth $47,000 after acquiring an additional 9,344 shares during the last quarter. Barclays PLC raised its holdings in shares of HilleVax by 255.6% during the 3rd quarter. Barclays PLC now owns 42,033 shares of the company’s stock worth $74,000 after acquiring an additional 30,213 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of HilleVax by 81.7% during the 3rd quarter. Jane Street Group LLC now owns 79,039 shares of the company’s stock worth $139,000 after acquiring an additional 35,546 shares in the last quarter. Finally, Zacks Investment Management boosted its position in shares of HilleVax by 411.9% during the 3rd quarter. Zacks Investment Management now owns 92,803 shares of the company’s stock valued at $163,000 after acquiring an additional 74,673 shares during the last quarter. Hedge funds and other institutional investors own 86.42% of the company’s stock.

HilleVax Stock Performance

Shares of HLVX opened at $1.59 on Friday. The stock has a market capitalization of $79.19 million, a PE ratio of -0.51 and a beta of 0.76. The company’s fifty day moving average is $1.82 and its 200 day moving average is $1.86. HilleVax, Inc. has a fifty-two week low of $1.55 and a fifty-two week high of $16.66.

HilleVax Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.